Table 3.
Demographic and medical data.
| Population | ||
|---|---|---|
| Variable | Efficacy + safety | HRQoL a |
| Number of patients enrolled, N | 82 | 48 b |
| Number of evaluable patients, N (%) | 82 (100%) | 30 (100%) |
| Sex, n (%) | ||
| Male | 34 (41%) | 19 (63%) |
| Female | 46 (56%) | 11 (37%) |
| Missing | 2 (2%) | 0 |
| Age (years), mean (range) | 34 (1-74) | 30 (3-74) |
| Age group, n (%) | ||
| < 14 years | 17 (21%) | 11 (37%) |
| ≥ 14 years | 65 (79%) | 19 (63%) |
| Diagnosis, n (%) | ||
| Common variable immunodeficiency | 44 (54%) | 11 (37%) |
| X-linked agammaglobulinaemia (Bruton disease) | 13 (16%) | 9 (30%) |
| Severe combined immunodeficiency | 4 (5%) | 1 (3%) |
| IgG subclass deficiency | 4 (5%) | 1 (3%) |
| Other congenital hypo- or agammaglobulinaemia | 5 (6%) | 2 (7%) |
| Secondary immunodeficiency | 9 (11%) | 5 (17%) |
| Missing | 3 (4%) | 1 (3%) |
| Prior treatment with immunoglobulins, n (%) | ||
| Intravenous infusions | 60 (73%) | 30 (100%) |
| Intramuscular infusions | 3 (4%) | 0 |
| Subcutaneous infusions | 12 (15%) | 0 |
| None | 6 (7%) | 0 |
| Missing | 1 (1%) | 0 |
a The HRQoL population is a subpopulation of the efficacy + safety population.
b Number of patients who completed the baseline HRQoL questionnaire.